Net revenues declined 25% to $12.5 million in 2025 from $16.7 million in 2024. The decrease in net revenues was primarily due to competition from generic L-Glutamine in the U.S. market, partially offset by increased sales in the Middle East North Africa (MENA) region. Income from operations was $0.2 million in 2025, a significant improvement from a $1.9 million loss in 2024. Total operating expenses were reduced by 34% to $11.4 million in 2025 from $17.3 million in 2024, attributed to headcount reduction and other cost-cutting measures. Net loss increased to $7.2 million, or $0.11 per share, in 2025, compared to a net loss of $6.5 million, or $0.10 per share, in 2024. The increase in net loss was primarily due to a rise in other expenses, including a $1.4 million increase in loss on debt extinguishment and a $1.4 million increase in interest expense. Cash and cash equivalents increased to $2.1 million at December 31, 2025, from $1.4 million at December 31, 2024. The company is undertaking a change in strategy for its U.S. operations by entering into a license and exclusive distribution arrangement with NeoImmuneTech, Inc., expected to be fully implemented in the second quarter of 2026.